Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy

Table 2 Risk factors for PFS by univariate and multiple Cox proportional hazards regression analysis

	Univariate Multivariate
Parameters	HR(95% CI)	p value	HR(95% CI)	p value
Age (high vs low)	1.18(0.98–1.46)	0.089	1.14(0.91–1.41)	0.131
Gender (male vs female)	1.12(0.72–1.73)	0.523
Current smokers (yes vs no)	1.33(0.82–2.05)	0.251
Alcohol (yes vs no)	1.03(0.83–1.29)	0.754
Diabetes (yes vs no)	1.21(0.94–1.52)	0.122
Hypertension (yes vs no)	1.47(0.79–2.58)	0.132
ECOG PS (0 vs ≥1)	0.86(0.71–1.07)	0.845
Tumor size (T1/T2 vs T3/T4)	0.78(0.39–1.55)	0.461
Lymph node (N0 vs N1–3)	1.92(0.89–3.78)	0.058	1.53(0.69–2.87)	0.205
Metastasis stage (M0 vs M1a/b)	1.79(1.15–2.64)	0.011*	1.73(1.15–2.59)	0.020*
Differentiation (Well/moderate vs poor)	1.74(1.03–2.88)	0.039*	1.60(0.89–2.73)	0.089
Histology (AC vs non-AC)	0.85(0.51–1.29)	0.407
Chemotherapy (DP vs AP/GP)	1.52(0.74–3.05)	0.245
CRP (high vs low)	0.86(0.71–1.07)	0.845
AFR (≤8.02 vs > 8.02)	2.07(1.32–3.12)	0.009*	1.80(1.09–2.78)	0.025*

NSCLC Non–small cell lung cancer, ECOG PS Eastern cooperative oncology group performance status, TNM Tumor–node–metastasis, SCC Squamous carcinoma, AC Adenocarcinoma, DP Docetaxel combined with platinum, AP Pemetrexed combined with platinum, GP Gemcitabine combined with platinum, CRP C-reactive protein, AFR Albumin-to-fibrinogen ratio, PFS Progression free survival, HR Hazard ratio, CI Confidence interval. *P < 0.05

ISSN: 1471-2407